Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Company Overview - Immix Biopharma, Inc. is a global leader in relapsed/refractory AL Amyloidosis, focusing on innovative therapies [4] - The lead candidate is NXC-201, a BCMA-targeted CAR-T cell therapy, currently evaluated in a multi-center study in the U.S. [4] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [4] Industry Insights - AL Amyloidosis is caused by abnormal plasma cells producing misfolded amyloid proteins, leading to organ failure and mortality [2] - The U.S. prevalence of relapsed/refractory AL Amyloidosis is estimated to grow at 12% annually, reaching approximately 37,270 patients by 2025 [2] - The Amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [3] Clinical Developments - Immix Biopharma will present a NXC-201 abstract at the American Society of Hematology (ASH) 67 Annual Meeting in December 2025 [1] - The primary endpoint of the NEXICART-2 study for NXC-201 was met at interim results presented at ASCO 2025 [4]